Hepatitis B screening before chemo deemed cost-effective

Share this article:
Hepatitis B Screening Before Chemo Deemed Cost-Effective
Hepatitis B Screening Before Chemo Deemed Cost-Effective

(HealthDay News) -- Universal hepatitis B virus (HBV) screening before chemotherapy for lymphoma reduces costs in most settings, according to a study published online June 18 in the Journal of Clinical Oncology.

Noting that potentially fatal HBV reactivation can be largely prevented with antiviral prophylaxis, Urszula Zurawska, M.D., from the University of Toronto, and colleagues developed a decision model to compare the clinical outcomes, costs, and cost-effectiveness of three HBV screening strategies for patients with lymphoma before rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. The strategies were: screen all patients for hepatitis B surface antigen (HBsAg; Screen-All), screen patients at high-risk for HBV infection (Screen-HR), and screen no one (Screen-None). Antiviral therapy was administered to screened patients who tested positive until six months after completion of chemotherapy. Those not screened were given antiviral therapy only if HBV hepatitis occurred. Costs were given in Canadian dollars and a third-party payer perspective was adopted.

The researchers found that the dominant strategy was Screen-All, costing $32,589, compared with $32,598 for Screen-HR and $32,657 for Screen-None. Screen-All was also associated with the highest one-year survival rate (84.99 percent), compared with Screen-HR and Screen-None (84.96 and 84.86 percent, respectively). The prevalence of HBsAg positivity in the low-risk population influenced analysis; when this value was ≤0.20 percent the Screen-HR became the least costly.

"In patients receiving R-CHOP for lymphoma, screening all patients for HBV reduces the rate of HBV reactivation (10-fold) and is less costly than screening only high-risk patients or screening no patients," the authors write.

One author disclosed financial ties to Gilead Sciences.

Abstract
Full Text

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Cancer 'vaccine' for advanced disease shows early progress

Cancer 'vaccine' for advanced disease shows early progress

Early progress has been made in developing a treatment that might one day help the immune system defend itself against cancer, but research is still in preliminary stages.

Clinician-patient relationship tied to health care outcomes

Clinician-patient relationship tied to health care outcomes

Meta-analysis of 13 randomized controlled trials shows small but significant effect from the patient-clinician relationship.

Patients see sharp increase in price of specialty drugs

Patients see sharp increase in price of specialty ...

Many Americans paying less for prescription drugs, but some are having to deal with sharp rises in cost of specialty meds.